Medipharm Labs Corp - MEDIF STOCK NEWS

Welcome to our dedicated page for Medipharm Labs news (Ticker: MEDIF), a resource for investors and traders seeking the latest updates and insights on Medipharm Labs stock.

MediPharm Labs Corp (MEDIF) is a leader in pharmaceutical-grade cannabis extraction and precision cannabinoid manufacturing, serving global medical markets through GMP-certified facilities. This page aggregates official news and verified updates about the company’s strategic initiatives, regulatory compliance milestones, and international expansion efforts.

Investors and industry professionals will find timely reports on earnings, partnership announcements, product innovations, and quality control advancements. Our curated collection simplifies tracking MEDIF’s progress in developing non-combustible delivery systems and expanding into regulated markets like Germany and Australia.

All content is sourced from company releases and accredited financial publications to ensure accuracy. Bookmark this page for streamlined access to MEDIF’s latest developments in pharmaceutical cannabis manufacturing, B2B white-label services, and API production.

02/07/2024 06:30 AM

News

MediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health Authority

Rhea-AI Summary

MediPharm Labs has received a GMP certificate from the Brazilian Health Regulatory Agency, ANVISA, making it the first pharmaceutical cannabis company in North America to do so. This certification allows the company to manufacture both active pharmaceutical ingredients (API) and end products for medical cannabis patients in Brazil. With a population of 215 million, Brazil has seen a 480% increase in medical cannabis prescriptions in 2022, indicating a significant market opportunity. The certification strengthens MediPharm's global position as a leader in the development and production of pharmaceutical cannabinoids, providing access to the Brazilian medical cannabis market and facilitating entry into additional global markets. The Brazilian medical cannabis market is expected to reach $380 million CAD in 2025, and MediPharm Labs currently manufactures two medical cannabis products with full ANVISA product authorization under Brazil's Resolution 327/19. The company has also entered into a supply agreement with a top-tier generic pharmaceutical company in Brazil, further expanding its market reach. The GMP certification was obtained after a rigorous inspection of MediPharm's manufacturing capabilities and quality management system, resulting in a compliant GMP status.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/22/2023 07:00 AM

News

MediPharm Labs Provides Update on Board of Directors and Long Term Incentive Program

Rhea-AI Summary

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced changes to its Board of Directors and employee stock issuance, including the resignation of a founding board member and the grant of 15.48 million stock options and 16.09 million restricted share units. The Company will continue with five board members, reflecting an overall right sizing of the business undertaken in 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.17%

Tags

11/14/2023 07:15 AM

News

MediPharm Labs Reports Third Quarter Results

Rhea-AI Summary

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced its financial results for Q3 2023, achieving higher gross margins and moving closer to profitability. The company settled a customer dispute for $9M, recorded a gross profit of $2.4M, improved adjusted EBITDA by 53%, and strengthened its balance sheet with $13M cash and less than $3M debt. Additionally, the company made significant progress in international medical cannabis growth and solidified its leadership in the cannabis-based pharmaceutical industry. Management's focus on margins, cost reductions, and profitability has positioned the company to make strategic investments for revenue growth, with M&A opportunities on the horizon.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.92%

Tags

11/08/2023 05:01 PM

News

MediPharm Labs Sets Date to Report Third Quarter 2023 Financial Results

Rhea-AI Summary

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) will release its Q3 financial results for the three and nine month periods ended September 30, 2023 on November 14, 2023. The executive team will host a conference call and webcast to discuss the results.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.92%

Tags

10/25/2023 07:00 AM

News

MediPharm Labs Update on $9M Settlement Agreement - All Tilray Shares Sold and Converted to Cash

Rhea-AI Summary

MediPharm Labs receives $7.27 million in cash and non-cash elements from settlement agreement with Tilray, strengthening the company's balance sheet.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.89%

Tags

10/02/2023 07:00 AM

News

MediPharm Labs Settles an Outstanding Claim for $9M

Rhea-AI Summary

MediPharm Labs settles an outstanding claim for $9M

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.66%

Tags

09/27/2023 07:15 AM

News

MediPharm Labs Launches new GMP Products to the Australian Medical Cannabis Market

Rhea-AI Summary

MediPharm Labs launches GMP products in Australian medical cannabis market

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.79%

Tags

09/20/2023 07:00 AM

News

MediPharm Labs Improves Domestic Sales Gross Margin with Termination of Shelter Cannabis Brands Royalty Agreement

Rhea-AI Summary

MediPharm Labs terminates royalty agreement with Shelter Cannabis Brands, resulting in improved gross margin and flexibility for further investment in driving sales.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.56%

Tags

09/05/2023 07:39 AM

News

MediPharm Labs Completes Sale of Vacant Land for Cash Proceeds of $1.9 million

Rhea-AI Summary

MediPharm Labs completes sale of vacant land for cash proceeds of $1.9 million

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.72%

Tags

08/31/2023 08:02 AM

News

MediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

Rhea-AI Summary

MediPharm Labs subsidiary Harvest Medicine published a study on Fibromyalgia and cannabis in the American Journal of Endocannabinoid Medicine. The study included over 800 patient assessments and showed a significant decrease in illness severity, depression, and anxiety scores. Medical cannabis may be effective in managing fibromyalgia and associated symptoms.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

14.29%

Tags